The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Improving the efficacy of antibody-based cancer therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Self-citationPresta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Isolation of high affinity human antibodies directly from large synthetic repertoires.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., & Allison, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06626.x · Cited by 962
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Lung biology in health and disease
Horsmanheimo, M., & Fudenberg, H. H. (1977) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(77)90040-x · Cited by 796
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
Boder, E. T., Midelfort, K. S., & Wittrup, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170297297 · Cited by 673
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.
Herlyn, M., Steplewski, Z., Herlyn, D., & Koprowski, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1438 · Cited by 656
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruı̈ne, A. P., Arends, J.-W., & Hoogenboom, H. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18218 · Cited by 533
Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1788 · Cited by 517
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Self-citationHuman anti-self antibodies with high specificity from phage display libraries.
Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., McCafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., & Hughes-Jones, N. C. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05706.x · Cited by 478
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Sheets, M. D., Amersdorfer, P., Finnern, R., Sargent, P., Lindqvist, E., Schier, R., Hemingsen, G., Wong, C., Gerhart, J. C., & Marks, J. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6157 · Cited by 438
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Lasic, D. D., & Papahadjopoulos, D. (1995) · Science · doi:10.1126/science.7871422 · Cited by 432
Press, O. W., Appelbaum, F., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 428
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1622 · Cited by 420
Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L. A., & Fisher, R. I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.389 · Cited by 417
Radioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 386
Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0598 · Cited by 382
Mendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X.-C., Maynard-Currie, C. E., Yang, X.-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376
Hanes, J., Schaffitzel, C., Knappik, A., & Plückthun, A. (2000) · Nature Biotechnology · doi:10.1038/82407 · Cited by 373
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Reshaping Human Antibodies: Grafting an Antilysozyme Activity
Verhoeyen, M., Milstein, C., & Winter, G. (1988) · Science · doi:10.1126/science.2451287 · Cited by 345
Yang, W.-P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., & Barbas III, C. F. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0626 · Cited by 333
Borgström, P., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1996) · PubMed · Cited by 331
Yang, X., Jia, X., Corvalan, J. R. F., Wang, P., Davis, C., & Jakobovits, A. (1999) · PubMed · Cited by 328
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
New protein engineering approaches to multivalent and bispecific antibody fragments
Plückthun, A., & Pack, P. (1997) · Immunotechnology · doi:10.1016/s1380-2933(97)00067-5 · Cited by 322
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
Effect of glycosylation on antibody function: implications for genetic engineering
Wright, A., & Morrison, S. L. (1997) · Trends in Biotechnology · doi:10.1016/s0167-7799(96)10062-7 · Cited by 312
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 311
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Clinical trials of antibody therapy
Glennie, M. J., & Johnson, P. W. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01669-8 · Cited by 288
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 267
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., & Wood, W. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1327 · Cited by 258
Self-citationLung Biology in Health and Disease
(2010) · Lung biology in health and disease · doi:10.1201/ihclubihedis · Cited by 256
Adams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., & Weiner, L. M. (1993) · PubMed · Cited by 248
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
SLAMON, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90188-5 · Cited by 243
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Tailoring in vitro evolution for protein affinity or stability
Jermutus, L., Honegger, A., Schwesinger, F., Hanes, J., & Plückthun, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.75 · Cited by 233
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Elucidation of the mechanism enabling tumor selective prodrug monotherapy.
Bosslet, K., Straub, R. H., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J., Koch, M. C., & Monneret, C. (1998) · PubMed · Cited by 225
Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J., & Pastan, I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140210597 · Cited by 216
Natural and designer binding sites made by phage display technology
Hoogenboom, H. R., & Chames, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01667-4 · Cited by 213
Nilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 212
Immune evasion of tumor cells using membrane-bound complement regulatory proteins
Gorter, A., & Meri, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01537-6 · Cited by 206
Dvorak, H. F., Nagy, J. A., & Dvořàk, A. M. (1991) · PubMed · Cited by 203
Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy
Zalutsky, M., & Vaidyanathan, G. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399275 · Cited by 202
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.
Burrows, F. J., & Thorpe, P. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.8996 · Cited by 198
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8618 · Cited by 196
Selection of tumor-specific internalizing human antibodies from phage libraries
Poul, M.-A., Becerril, B., Nielsen, U. B., Morisson, P., & Marks, J. D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4026 · Cited by 192
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
Sampson, J. H., Crotty, L. E., Lee, S., Archer, G. E., Ashley, D. M., Wikstrand, C. J., Hale, L. P., Small, C., Dranoff, G., Friedman, A. H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130166597 · Cited by 188
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
Mann, M., Sheng, H., Shao, J., Williams, C. S., Dubois, R. N., Pisacane, P. I., & Sliwkowski, M. X. (2001) · Gastroenterology · doi:10.1053/gast.2001.24844 · Cited by 179
Lifely, M. R., Hale, C., Boyce, S., Keen, M. J., & Phillips, J. (1995) · Glycobiology · doi:10.1093/glycob/5.8.813 · Cited by 178
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161
Of mice and men: hybridoma and recombinant antibodies
Little, M., Kipriyanov, S. M., Gall, F. L., & Moldenhauer, G. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01668-6 · Cited by 160
Vaughan, T. J., Osbourn, J. K., & Tempest, P. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0698-535 · Cited by 158
Immunotherapeutic perspective for bispecific antibodies
van Spriel, A. B., van Ojik, H. H., & van de Winkel, J. G. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01659-5 · Cited by 133
Anti-HER2 immunoliposomes for targeted therapy of human tumors
Park, J. W., Hong, K., Kirpotin, D. B., Meyer, O., Papahadjopoulos, D., & Benz, C. C. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00326-1 · Cited by 130
Chinol, M., Casalini, P., Maggiolo, M. J., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.463 · Cited by 123
Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates
Zalutsky, M. R., & Bigner, D. D. (1996) · Acta Oncologica · doi:10.3109/02841869609101654 · Cited by 121
Immunoliposomes for Cancer Treatment
Park, J. W., Hong, K., Kirpotin, D. B., et al. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60146-5 · Cited by 115
Ghetie, M.-A., Podar, E. M., Ilgen, A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7509 · Cited by 112
Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., & Reisfeld, R. A. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00033-3 · Cited by 96
Syrigos, K. N., & Epenetos, A. A. (1999) · PubMed · Cited by 87
Antibody–cytokine fusion proteins for the therapy of cancer
Penichet, M. L., & Morrison, S. L. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00345-8 · Cited by 80
Bendas, G. (2001) · BioDrugs · doi:10.2165/00063030-200115040-00002 · Cited by 74
Rybak, S. M., Hoogenboom, H. R., Meade, H., et al. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3165 · Cited by 73
Suzuki, M., Saxena, S. K., Boix, E., et al. (1999) · Nature Biotechnology · doi:10.1038/7010 · Cited by 69
Smith, G. K., Banks, S. D., Blumenkopf, T. A., Cory, M., Humphreys, J. E., Laethem, R. M., Miller, J. F., Moxham, C. P., Mullin, R. J., Ray, P. H., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15804 · Cited by 68
Fitzpatrick, V. D., Pisacane, P. I., VANDLEN, R. L., & Sliwkowski, M. X. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00737-6 · Cited by 67
Targeted Cytokines for Cancer Immunotherapy
Lode, H. N., & Reisfeld, R. A. (2000) · Immunologic Research · doi:10.1385/ir:21:2-3:279 · Cited by 61
Nicholson, I., Zou, X., Popov, A. V., et al. (1999) · PubMed · Cited by 55
Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu‐Duvaz, I., Friedlos, F., Niculescu‐Duvaz, D., et al. (1999) · PubMed · Cited by 51
Nicholson, I., Zou, X., Popov, A. V., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6898 · Cited by 50
A potential role for activated HER-2 in prostate cancer.
Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., & Sliwkowski, M. X. (2000) · PubMed · Cited by 41
Engineered humanized dimeric forms of IgG are more effective antibodies.
Caron, P. C., Laird, W., Co, M. S., Avdalovic, N. M., Queen, C., & Scheinberg, D. A. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1191 · Cited by 40
Antibodies as Carriers of Cytotoxicity
Sedlacek, H. H., Seemann, G., Hoffmann, D., et al. (1992) · Beiträge zur Onkologie/Contributions to oncology · doi:10.1159/isbn.978-3-318-03426-4 · Cited by 40
Antibody-Based Targeting of Angiogenesis
Halin, C., & Neri, D. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i3.20 · Cited by 32
Recent developments in the radioimmunotherapy of cancer
Jurcic, J. G., & Scheinberg, D. A. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90074-4 · Cited by 30
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Metadata
- Authors
- Carter, P.
- Venue
- Nature Reviews Cancer
- Published
- 2001-11-01
- Volume
- 1
- Issue
- 2
- Pages
- 118-129
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1512026049
- Cited by
- 833
- References
- 118
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.